Longitudinal antibody repertoire in "mild" versus "severe" COVID-19 patients reveals immune markers associated with disease severity and resolution. Academic Article uri icon

Overview

abstract

  • Limited knowledge exists on immune markers associated with disease severity or recovery in patients with coronavirus disease 2019 (COVID-19). Here, we elucidated longitudinal evolution of SARS-CoV-2 antibody repertoire in patients with acute COVID-19. Differential kinetics was observed for immunoglobulin M (IgM)/IgG/IgA epitope diversity, antibody binding, and affinity maturation in "severe" versus "mild" COVID-19 patients. IgG profile demonstrated immunodominant antigenic sequences encompassing fusion peptide and receptor binding domain (RBD) in patients with mild COVID-19 who recovered early compared with "fatal" COVID-19 patients. In patients with severe COVID-19, high-titer IgA were observed, primarily against RBD, especially in patients who succumbed to SARS-CoV-2 infection. The patients with mild COVID-19 showed marked increase in antibody affinity maturation to prefusion SARS-CoV-2 spike that associated with faster recovery from COVID-19. This study revealed antibody markers associated with disease severity and resolution of clinical disease that could inform development and evaluation of effective immune-based countermeasures against COVID-19.

publication date

  • March 5, 2021

Research

keywords

  • Antibodies, Viral
  • Antigens, Viral
  • Biomarkers
  • COVID-19
  • SARS-CoV-2
  • Severity of Illness Index

Identity

PubMed Central ID

  • PMC7935365

Scopus Document Identifier

  • 85102078770

Digital Object Identifier (DOI)

  • 10.1126/sciadv.abf2467

PubMed ID

  • 33674317

Additional Document Info

volume

  • 7

issue

  • 10